trifluridine tipiracil drug combination

trifluridine tipiracil combination for treatment of colorectal cancer; a 1:0.5 mixture of viroptic and 5-chloro-6-(1-(2-iminopyrrolidinyl)methyl)uracil (5-CIMU); an antimetabolite with antineoplastic activity; tipiracil inhibits thymidine phosphorylase

Also Known As:

Networked: 414 relevant articles (93 outcomes, 166 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Yoshino, Takayuki: 21 articles (07/2021 - 10/2012)
2.	Yamazaki, Kentaro: 17 articles (07/2021 - 10/2012)
3.	Shitara, Kohei: 14 articles (01/2022 - 01/2016)
4.	Nakagawa, Fumio: 13 articles (07/2021 - 02/2004)
5.	Oki, Eiji: 13 articles (07/2021 - 04/2015)
6.	Ohtsu, Atsushi: 13 articles (12/2018 - 10/2012)
7.	Doi, Toshihiko: 11 articles (01/2022 - 10/2015)
8.	Makris, Lukas: 11 articles (01/2022 - 05/2015)
9.	Denda, Tadamichi: 10 articles (07/2021 - 01/2018)
10.	Komatsu, Yoshito: 10 articles (07/2021 - 10/2012)

Related Diseases

1.	Colorectal Neoplasms (Colorectal Cancer) 01/01/2020 - "In RECOURSE (, trifluridine/tipiracil significantly improved overall survival and progression-free survival (PFS) versus placebo in patients with pretreated metastatic colorectal cancer (mCRC). " 01/01/2019 - "Treatment with TAS-102 has significantly improved the progression-free survival (PFS) and overall survival (OS) of patients with metastatic colorectal cancer (mCRC). " 07/01/2018 - "TAS-102 has led to a significant improvement in overall survival (OS) and progression-free survival (PFS) of patients with metastatic colorectal cancer (mCRC). " 01/01/2018 - "Beneficial Treatment Management with Trifluridine/Tipiracil in a Patient with Metastatic Colorectal Cancer and Pronounced Hematological Event History during Previous Treatments." 05/14/2015 - "In patients with refractory colorectal cancer, TAS-102, as compared with placebo, was associated with a significant improvement in overall survival. "
2.	Neoplasms (Cancer) 04/01/2022 - "As promising results have already been observed in the chemorefractory gastric and gastroesophageal-junction cancers, ongoing trials are assessing the use of trifluridine/tipiracil with other standard of care agents, aiming to further improve the survival rate of these patients." 01/01/2023 - "Phase 1 study of the safety, pharmacokinetics, and preliminary efficacy of CA102N as monotherapy and in combination with trifluridine-tipiracil in patients with locally advanced or metastatic solid tumors." 12/01/2022 - "Trifluridine/tipiracil (FTD/TPI) showed clinical benefit, including improved survival and manageable safety in previously treated patients with metastatic colorectal (mCRC) or gastric/gastroesophageal junction (mGC/GEJC) cancer in the phase III RECOURSE and TAGS trials, respectively. " 01/01/2020 - "Pharmacokinetics, Safety, and Preliminary Efficacy of Oral Trifluridine/Tipiracil in Chinese Patients with Solid Tumors: A Phase 1b, Open-Label Study." 01/01/2020 - "Trifluridine/tipiracil (FTD/TPI) has activity in both fluoropyrimidine-sensitive and -resistant tumors, which led us to conduct a single arm phase II trial to evaluate the safety and efficacy of FTD/TPI for patients previously treated for advanced BTC. "
3.	Stomach Neoplasms (Stomach Cancer) 01/01/2020 - "In TAGS, an international, double-blind, phase 3 trial, trifluridine/tipiracil significantly improved overall survival and progression-free survival compared with placebo in heavily pretreated metastatic gastric cancer patients. " 11/01/2018 - "Trifluridine/tipiracil significantly improved overall survival compared with placebo and was well tolerated in this heavily pretreated population of patients with advanced gastric cancer. " 01/01/2022 - "A trial with trifluridine/tipiracil (FTD/TPI) versus placebo in patients with heavily pretreated metastatic gastric cancer showed that FTD/TPI is effective with manageable toxicity in these patients. " 12/01/2021 - "TAS-102 is effective against unresectable advanced or recurrent colorectal and gastric cancer. " 01/15/2021 - "This study provides clear evidence to evaluate the effectiveness and safety of trifluridine/tipiracil for patients with highly pretreated metastatic gastric cancer, and the findings will also be published in a peer-reviewed journal. "
4.	Colonic Neoplasms (Colon Cancer) 01/15/2007 - "TAS-102 is only effective in inducing cytotoxicity when systemic TPI is present, but acts against both low and high TP expressing colon cancer cells, while 5'DFUR needs cellular TP to exert significant activity." 01/01/2023 - "Complete response to third-line treatment with trifluridine/tipiracil (TAS-102) in stage IV colon adenocarcinoma." 05/01/2015 - "Positron emission tomography imaging of human colon cancer xenografts in mice with [18F]fluorothymidine after TAS-102 treatment." 01/01/2020 - "The aim of this study was to investigate possible synergistic effects in vitro of trifluridine/tipiracil (TAS-102) and 5-fluoruracil (5-FU) on fluoropyrimidine-sensitive colon cancer cell lines of different mutational status in order to build a rational basis for the future use of this combination therapy in adjuvant settings or as a first-line treatment for metastatic disease. " 01/01/2021 - "Recently, studies have reported the efficacy of TAS-102 combined with bevacizumab in colon cancer patients after standard treatment fails. "
5.	Adenocarcinoma 01/01/2020 - "Clinical Evaluation of the Safety and Efficacy of Trifluridine/Tipiracil in the Treatment of Advanced Gastric/Gastroesophageal Junction Adenocarcinoma: Evidence to Date." 11/26/2021 - "Trifluridine/tipiracil (TAS-102) is a newer generation chemotherapy that has been approved for the later-line treatment of metastatic colorectal and gastric/gastroesophageal adenocarcinomas. " 09/01/2019 - "Thus, trifluridine/tipiracil provides a valuable and much needed treatment option for patients with metastatic gastric or gastroesophageal junction adenocarcinoma that has progressed on at least two prior therapies." 05/01/2010 - "These results led us to consider that TAS-102 may also be effective for esophageal and uterine squamous cell carcinomas, as well as for gastrointestinal adenocarcinomas, even in fluoropyrimidine-resistant cases with high TS expression. " 03/01/2022 - "Cost-effectiveness of trifluridine/tipiracil as a third-line treatment of metastatic gastric cancer, including adenocarcinoma of the gastrohesophageal junction, among patients previously treated in Greece."

Related Drugs and Biologics

1.	Bevacizumab (Avastin)
2.	trifluridine tipiracil drug combination
3.	regorafenib
4.	Irinotecan (Camptosar)
5.	Capecitabine (Xeloda)
6.	Fluorouracil (Carac)
7.	Nucleosides
8.	Panitumumab (Vectibix)
9.	Trifluridine (Viroptic)
10.	tipiracil

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Combination Drug Therapy (Combination Chemotherapy)
4.	Duration of Therapy
5.	Immunotherapy